Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

Why Fast-Track Cancer Drugs Don’t Always Mean Better Care

30 Oct 2025 · 0 min

Watch on YouTube

0:28

In this commentary, the speaker critiques the FDA’s fast‑track approval pathway for cancer drugs, arguing that it allows medications to reach the market without demonstrating substantial improvement over existing therapies. The speaker notes that these fast‑tracked drugs are often only marginally better, come with significantly higher prices, and typically manage cancer rather than achieve full remission, extending patients’ lives by only a few months. He frames this as part of a broader "cancer industrial complex" that drives up costs while delivering limited clinical benefit, and encourages viewers to explore his other videos for deeper analysis.

If we go back and look at these drugs the way they're approved, this is how it's done. Big pharma does fast track with fda, means it gets it approved, sometimes faster. The drug doesn't have to be much better than an existing drug on the market. It's much more expensive. It's managing the cancer, often not bringing it into full remission like we want. And then this gets moved on down the pipeline of the cancer industrial complex. You may want to watch my other videos to learn about those. And it increases the cost, but only improves life expectancy, maybe by a few months.